Response Genetics, Inc. to Release Fourth Quarter and Year-End 2013...
Response Genetics, Inc. , a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, will announce its fourth quarter and year-end financial results for 2013 and give an operational update in a press release to be issued before the market opens on Thursday, March 20, 2014.
Response Genetics, Inc. to Offer Expanded KRAS Mutation Test to...
Response Genetics, Inc. , a company focused on the development and sale of molecular diagnostic tests for cancer today announced the commercial availability of its expanded KRAS assay, a mutation detection test that provides broader coverage of KRAS mutations, including those in regions of the gene not previously examined.
Response Genetics: Gearing Up For A Run
There's a gamble with some upside out there in Response Genetics, . It is a micro-crap stock trading on the NASDAQ stock exchange currently with a market cap of approximately $50 million.